id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-334235-ymsiihwd	Gray, Belinda	Patients with Genetic Heart Disease and COVID-19: A Cardiac Society of Australia and New Zealand (CSANZ) Consensus Statement	2020-04-30		.txt	text/plain	1181	75	48	Abstract In the context of the current global COVID-19 pandemic, this Consensus Statement provides current recommendations for patients with, or at risk of developing, genetic heart disease, and for their health care management and service provision in Australia and New Zealand. However, we have identified areas of consensus among specialists from the Cardiac Society of Australia and New Zealand (CSANZ) Cardiovascular Genetics Diseases Council with regards to managing patients with genetic heart disease in this current COVID-19 pandemic. [4] ; key points as below: o QT interval monitoring for all patients commenced on hydroxychloroquine or when combining anti-viral drugs for COVID-19 o Avoid the use of more than one medication which prolongs the QT interval as far as is possible o If the corrected QT interval (QTc) is consistently >500ms, we recommend consultation with a cardiogenetics expert or an electrophysiologist for guidance on further management to minimise risk of Torsade de Pointes.	./cache/cord-334235-ymsiihwd.txt	./txt/cord-334235-ymsiihwd.txt